RxDoctor Payments Data

Victoria Bellot, MD

Nephrology · Rego Park, NYNPI 1417993932

Payments from drug & device makers

$21,758in general payments, 2019–2025

Across 392 payments — averaging $55.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$8K
  • Otsuka America Pharmaceutical, Inc.$7K
  • Amgen$1K
  • OPKO Pharmaceuticals, LLC$946
  • Akebia Therapeutics Inc$638
  • Novo Nordisk$559
  • plus $3K from 17 others

What the payments were for

  • Consulting fees$5,28024%
  • Speaking & faculty fees$6,15028%
  • Travel & lodging$4932%
  • Food & beverage$8,77940%
  • Education$1,0555%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,758 in reported general payments places this provider in the 85th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York

Medicare billing

Part B allowed, 2024
$298,036
Medicare patients
267
Services billed
2,954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$152,626
FarxigaDapagliflozin Propanediol157$146,879
LokelmaSodium Zirconium Cyclosilicate144$113,898
JardianceEmpagliflozin79$80,614
VelphoroSucroferric Oxyhydroxide28$69,988
KerendiaFinerenone66$67,818
ProcritEpoetin Alfa28$65,175
MounjaroTirzepatide57$58,233
JanuviaSitagliptin Phosphate50$49,909
AuryxiaFerric Citrate27$37,244
VeltassaPatiromer Calcium Sorbitex22$27,118
RayaldeeCalcifediol11$19,335
LinzessLinaclotide19$16,300
VascepaIcosapent Ethyl18$11,323
DapagliflozinDapagliflozin Propanediol11$10,986

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$7,936$260,777301 claims
Novo NordiskOzempic$559$152,626104 claims
Boehringer IngelheimJardiance$558$80,61479 claims
Fresenius USA Marketing, Inc.Velphoro$322$69,98828 claims
Lilly USA, LLCMounjaro, Trulicity$221$68,14168 claims
BayerKerendia$283$67,81866 claims
MerckJanuvia$133$49,90950 claims
Akebia Therapeutics IncAuryxia$638$37,24427 claims
OPKO Pharmaceuticals, LLCRayaldee$946$19,33511 claims
GSKShingrix$113$4,45324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 935 nephrology providers in New York.

Other nephrology in Rego Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →